A pharmacologic effecacy of the dabigatran in complex treatment of venous thromboembolizm

Abstract


An analysis of complex examination and treatment of 55 patients suffered by venous thromboembolizm has been completed. All patients were randomized into two groups. The fi rst (control) group included 30 patients. In the group treatment started with 7 day course heparin therapy followed by 6 month warfarin intake. The second (investigated) group consisted of 25 patients. For their treatment a dabigatran etaxilate was used instead of the warfarin. It was noticed that there were no recurrence of the disease in the fi rst group. However the disease relapsed in the second group in 1(4%) patients resulted from resistancy to anticoagulation therapy and inherent thrombophylia. Complications of the anticoagulation therapy have developed in 20% of patients in the fi rst and 16% of patients in the second group respectively.

Курский государственный медицинский университет

Author for correspondence.
Email: kaf.obsh_hir@kurskmed.com
д.м.н., профессор, заведующий кафедрой общей хирургии Курского государственного медицинского университета

Городская клиническая больница скорой медицинской помощи, г. Курск

Email: kaf.obsh_hir@kurskmed.com
врач-хирург сосудистого отделения городской клинической больницы скорой медицинской помощи г. Курска

Городская клиническая больница скорой медицинской помощи, г. Курск

Email: kaf.obsh_hir@kurskmed.com
врач-лаборант городской клинической больницы скорой медицинской помощи г. Курска

Городская клиническая больница скорой медицинской помощи, г. Курск

Email: kaf.obsh_hir@kurskmed.com
врач-лаборант городской клинической больницы скорой медицинской помощи г. Курска;

  • Ginzburg V., Grinberg G., Maizler O., Sandro G. Regionarnaia tromboliticheskaia terapiia proksimal'nogo (podvzdoshno-bedrennogo) venoznogo tromboza. Vestnik eksperimental'noi i klinicheskoi khirurgii 2009; 2: 2: 116-121.
  • Zatevakhin I.I., Tsitsiashvili M.Sh., Mishnev A.D., Trusov O.A., Matiushkin A.V. Posleoperatsionnye venoznye tromboembolicheskie oslozhneniia. Naskol'ko real'na ugroza? Angiologiia i sosudistaia khirurgiia 2002; 1: 17-21.
  • Kirienko A.I., Leont'ev S.G., Lebedev I.S., Seliverstov E.I. Profilaktika venoznykh tromboembolicheskikh oslozhnenii v khirurgicheskoi klinike. Sonsiliun medicum 2006; 7: 78-80.
  • Pokrovskii A.V. Klinicheskaia angiologiia. M.: Meditsina 2004;.2; 888.
  • Savel'ev V.S. Flebologiia. M.: Meditsina 2001; 664. 6. Sapelkin S.V. XVI Vsemirnyi kongress mezhdunarodnogo soiuza flebologov – obzor materialov kongressa. Angiologiia i sosudistaia khirurgiia 2009; 4: 81-85.
  • Shevchenko Iu.L., Stoiko Iu.M., Lytkin M.I. Osnovy klinicheskoi flebologii. M.: Meditsina 2005; 348.
  • Eriksson B.I., Dahl O.E., Rosencher N. et al. Dabigatran etexilate compared with enoxaparin for the extended prevention of venous thromboembolism following total hip replacement. Lancet. 2007; 370: 949-956.
  • Geerts W.H., Pieno G.F., Heit J.A. et al. Prevention of Venous thromboembolism: The Seventh ACCP Conference on antithrombic Thrombolytic therapy. Chest. 2004; 126: 335-400.
  • Stangier J., Rathgen K., Staehle H. et. al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007; 64:292303.

Views

Abstract - 46

PDF (Russian) - 14


Copyright (c) 2011 ., ., ., .

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.